. SchwarzschildMA, ChenJF, AscherioA. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology2002; 58: 1154–60.
2.
. MaiaL, de MendoncaA. Does caffeine intake protect from Alzheimer's disease?Eur J Neurol2002; 9: 377–82.
3.
. FredholmBB, BattigK, HolmenJ, NehligA, ZvartauEE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev1999; 51: 83–133.
4.
. ChenJF, XuK, PetzerJP, StaalR, XuYH, BeilsteinM, Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci2001; 21: RC143.
5.
. PratG, RobledoP, RubioA, BarbanojM, JaneF, CasasM. Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats. Brain Res2000; 868: 376–9.
6.
. Dall'IgnaOP, PorciunculaLO, SouzaDO, CunhaRA, LaraDR. Neuroprotection by caffeine and adenosine A2A receptor blockade of β-amyloid neurotoxicity. Br J Pharmacol2003; 138: 1207–9.
7.
. BlumD, GalasMC, PintorA, BrouilletE, LedentC, MullerCE, A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J Neurosci2003; 23: 5361–9.
8.
. AcquasE, TandaG, Di ChiaraG. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naïve and caffeine-pretreated rats. Neuropsychopharmacology2002; 27: 182–93.
9.
. BriceCF, SmithAP. Effects of caffeine on mood and performance: a study of realistic consumption. Psychopharmacology (Berl)2002; 164: 188–92.
10.
. RiedelW, HogervorstE, LebouxR, VerheyF, van PraagH, JollesJ. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl)1995; 122: 158–68.
11.
. RossGW, AbbottRD, PetrovitchH, MorensDM, GrandinettiA, TungKH, Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA2000; 283: 2674–9.
12.
. XuK, XuYH, ChenJF, SchwarzschildMA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett2002; 322: 13–6.
13.
. DoraiswamyPM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs2002; 16: 811–24.
14.
. RockwoodK, KirklandS, HoganDB, MacKnightC, MerryH, VerreaultR, Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol2002; 59: 223–7.
15.
. ShoulsonI, OakesD, FahnS, LangA, LangstonJW, LeWittP, Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol2002; 51: 604–12.
. ReisbergB, DoodyR, StofflerA, SchmittF, FerrisS, MobiusHJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med2003; 348: 1333–41.
18.
. JackCR, SlomkowskiM, GraconS, HooverTM, FelmleeJP, StewartK, MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology2003; 60: 253–60.
